---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-000830"
form_type: "8-K"
ticker: "VERA"
cik: "0001831828"
company_name: "Vera Therapeutics, Inc."
filed_at: "2023-01-03T23:59:59+00:00"
generated_at: "2026-06-20T21:00:58.851285+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Vera Therapeutics reports positive Phase 2b ORIGIN topline: primary endpoint met in IgA nephropathy

## Summary
- UPCR reduced 31% with pooled 75/150 mg dose (p=0.037 vs placebo) and 33% with 150 mg (p=0.047) at week 24.
- eGFR stabilized in atacicept arm through week 24; Gd-IgA1 reduced robustly from baseline.
- Safety well-tolerated: 1% discontinuation due to AEs, serious TEAEs 2% atacicept vs 9% placebo.
- Company plans to advance atacicept into pivotal Phase 3 development in H1 2023 subject to FDA discussions.

## SEC filing metadata
- accession: 0001193125-23-000830
- form_type: 8-K
- ticker: VERA
- cik: 0001831828
- company_name: Vera Therapeutics, Inc.
- filed_at: 2023-01-03T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1831828/000119312523000830/0001193125-23-000830-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1831828/000119312523000830/d445567d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-000830
- JSON: https://secwatch.observer/filing/0001193125-23-000830.json
- Plain text: https://secwatch.observer/filing/0001193125-23-000830.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.